<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">ANP</journal-id>
<journal-id journal-id-type="hwp">spanp</journal-id>
<journal-title>Australian &amp; New Zealand Journal of Psychiatry</journal-title>
<issn pub-type="ppub">0004-8674</issn>
<issn pub-type="epub">1440-1614</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0004867411432076</article-id>
<article-id pub-id-type="publisher-id">10.1177_0004867411432076</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Articles</subject>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Frontotemporal dementia as a frontostriatal disorder: Neostriatal morphology as a biomarker and structural basis for an endophenotype</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Looi</surname><given-names>Jeffrey CL</given-names></name>
<xref ref-type="aff" rid="aff1-0004867411432076">1</xref>
<xref ref-type="aff" rid="aff2-0004867411432076">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Walterfang</surname><given-names>Mark</given-names></name>
<xref ref-type="aff" rid="aff3-0004867411432076">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Velakoulis</surname><given-names>Dennis</given-names></name>
<xref ref-type="aff" rid="aff3-0004867411432076">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Macfarlane</surname><given-names>Matthew D</given-names></name>
<xref ref-type="aff" rid="aff1-0004867411432076">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Svensson</surname><given-names>Leif Anders</given-names></name>
<xref ref-type="aff" rid="aff4-0004867411432076">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Wahlund</surname><given-names>Lars-Olof</given-names></name>
<xref ref-type="aff" rid="aff2-0004867411432076">2</xref>
</contrib>
</contrib-group>
<aff id="aff1-0004867411432076"><label>1</label>Research Centre for the Neurosciences of Ageing, Academic Unit of Psychological Medicine, Australian National University Medical School, Canberra Hospital, Canberra, Australia</aff>
<aff id="aff2-0004867411432076"><label>2</label>Karolinska Institute, Department of Neurobiology, Caring Sciences &amp; Society, Division of Clinical Geriatrics, Stockholm, Sweden</aff>
<aff id="aff3-0004867411432076"><label>3</label>Melbourne Neuropsychiatry Centre, Royal Melbourne Hospital &amp; University of Melbourne, Melbourne, Australia</aff>
<aff id="aff4-0004867411432076"><label>4</label>Karolinska University Hospital, Hospital Physics and Radiology, Stockholm, Sweden</aff>
<author-notes>
<corresp id="corresp1-0004867411432076">Jeffrey Looi, Research Centre for the Neurosciences of Ageing, Academic Unit of Psychological Medicine, Australian National University Medical School, Building 4, Level 2, The Canberra Hospital, PO Box 11, Woden, ACT 2605, Australia. Email: <email>jeffrey.looi@anu.edu.au</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>5</month>
<year>2012</year>
</pub-date>
<volume>46</volume>
<issue>5</issue>
<fpage>422</fpage>
<lpage>434</lpage>
<permissions>
<copyright-statement>© The Royal Australian and New Zealand College of Psychiatrists 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">The Royal Australian and New Zealand College of Psychiatrists</copyright-holder>
</permissions>
<abstract>
<p><bold>Objective:</bold> This article reviews the evidence for a re-conceptualisation of a subtype of frontotemporal lobar degeneration (FTLD), frontotemporal dementia (FTD), as a frontostriatal disorder, working towards an endophenotype.</p>
<p><bold>Method:</bold> We provide an overview of the role of frontostriatal circuits relevant to FTLD and FTD, as a subset of larger-scale distributed brain networks. We discuss the role of a strategic structure in these circuits, the neostriatum. Then we review the relationship of the clinical features of FTLD to frontostriatal circuits, correlating this with neuropsychological and neuropathological data.</p>
<p><bold>Conclusion:</bold> The unique structure and linkages of the neostriatum make it an ideal structure for in vivo neuroimaging to understand the neuroanatomical basis of FTD. We develop a frontostriatal endophenotypic model for FTD as a platform for further investigation.</p>
</abstract>
<kwd-group>
<kwd>Dementia</kwd>
<kwd>striatum</kwd>
<kwd>neuroimaging</kwd>
<kwd>biomarkers</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0004867411432076" sec-type="intro">
<title>Introduction: FTLD as a selective neurodegeneration resulting in neural circuit dysfunction</title>
<p><disp-quote><p><italic>Nature uses only the longest threads to weave her patterns, so that each small piece of her fabric reveals the organization of the entire tapestry.</italic></p>
<attrib>(<xref ref-type="bibr" rid="bibr16-0004867411432076">Feynman, 1994</xref>, p.75)</attrib></disp-quote></p>
<p>The frontotemporal lobar degenerations (FTLD) have onset typically in the sixth and seventh decades, and as such are devastating for mature adults, leading to a rapid decline and resultant early death, often under a decade from diagnosis (<xref ref-type="bibr" rid="bibr49-0004867411432076">Mocellin et al., 2008</xref>). Thus, early diagnosis and development of reliable biomarkers to assess the progress of the illness are crucial for patients and their families to both stage and plan for difficulties that will arise due to cognitive decline, and to develop innovative treatments.</p>
<p>Recent neuropathological and neuroimaging studies of FTLD have converged upon the investigation of neural circuits or networks (<xref ref-type="bibr" rid="bibr48-0004867411432076">Mesulam, 2009</xref>; <xref ref-type="bibr" rid="bibr60-0004867411432076">Seeley et al., 2008</xref>, <xref ref-type="bibr" rid="bibr61-0004867411432076">2009</xref>). The fronto-striato-pallido-thalamo-cortical re-entrant neural circuits (<xref ref-type="bibr" rid="bibr11-0004867411432076">Cummings, 1993</xref>) (<xref ref-type="fig" rid="fig1-0004867411432076">Figure 1</xref>) are subsystems of large-scale neural networks under investigation as structural–functional substrates for the clinical features of FTLD and in particular, the frontotemporal dementia (FTD) subtype. Neuroplastic structural change in the frontostriatal circuits may manifest as morphological change. Network disruption may arise from loss of function from any node within the circuit. Key nodes that may be disrupted by neuropathological change are the frontal lobes and the striatum, together with the interconnecting white matter. Similarly, thalamus and globus pallidus may be affected. Within frontostriatal circuits, the neostriatum, comprising the caudate nucleus and putamen, occupies a central strategic role as a neural relay centre, with specific linkages to frontal and parietal cortex (<xref ref-type="bibr" rid="bibr15-0004867411432076">Draganski et al., 2008</xref>). While specific morphological and functional change of the cortical regions, and to a lesser extent white matter, have been extensively investigated in FTD, there has been less interest in the striatum. However, the specific interconnections of the striatum to frontal and related cortex may allow the striatum to serve as a miniature map of the corresponding morphological change in other nodes of the frontostriatal circuits. Accordingly, the specific morphology of the caudate nucleus and putamen may correspond to morphological, and hence functional change, in the neural circuits relayed. It is acknowledged that structural and functional changes in cortex and white matter may represent the primary changes in FTD; however, the measurement of such morphological change as a clinically useful biomarker is likely to remain elusive due to the inter-individual variation in frontal cortical morphology, and the relative complexity of white matter morphology in FTD. Disruption of any component of the frontostriatal circuits will potentially affect network functions, and such network disruption may have up- and downstream effects due to trans-synaptic neurodegeneration (<xref ref-type="bibr" rid="bibr6-0004867411432076">Buren, 1963</xref>). Thus, it is possible that circuit-based dysfunction and morphological change may be reflected, at least in part, in all nodes of the circuits (<xref ref-type="bibr" rid="bibr34-0004867411432076">Looi, 2011</xref>). Given that the striatum occupies a strategic nodal location, and the close correspondence of striatal structure to its interconnections, the striatum may be a key structure in which morphological change may be detectable (<xref ref-type="bibr" rid="bibr34-0004867411432076">Looi, 2011</xref>).</p>
<fig id="fig1-0004867411432076" position="float">
<label>Figure 1.</label>
<caption><p>Frontostriatal circuits.</p>
<p>Striatum: caudate nucleus, nucleus accumbens and putamen</p>
<p>GP: globus pallidus</p>
<p>SN: substantia nigra</p></caption>
<graphic xlink:href="10.1177_0004867411432076-fig1.tif"/>
</fig>
<p>There is burgeoning neuropathological and neuroimaging evidence that the striatum is affected early and significantly in FTLD, with differentiation based upon subtype due to relative degrees of frontostriatal circuit involvement (<xref ref-type="bibr" rid="bibr10-0004867411432076">Chow et al., 2008</xref>, <xref ref-type="bibr" rid="bibr17-0004867411432076">Garibotto et al., 2011</xref>; <xref ref-type="bibr" rid="bibr35-0004867411432076">Looi et al., 2008</xref>, <xref ref-type="bibr" rid="bibr37-0004867411432076">2009</xref>, <xref ref-type="bibr" rid="bibr39-0004867411432076">2010</xref>). Striatal atrophy may thus be an early biomarker of FTD, and a harbinger of frontostriatal circuit neurodegeneration (<xref ref-type="bibr" rid="bibr39-0004867411432076">Looi et al., 2010</xref>, <xref ref-type="bibr" rid="bibr38-0004867411432076">2011a</xref>). The frontostriatal circuits comprise pathways involved with cognitive, emotional, behavioural and motor functions. Accordingly, dysfunction may be manifest in these domains, and can be observed clinically. Our morphological studies, together with similar studies by other groups, have demonstrated that caudate, and to a lesser extent, putaminal atrophy is characteristic of FTLD compared to Alzheimer’s disease and controls (<xref ref-type="bibr" rid="bibr10-0004867411432076">Chow et al., 2008</xref>, <xref ref-type="bibr" rid="bibr17-0004867411432076">Garibotto et al., 2011</xref>; <xref ref-type="bibr" rid="bibr35-0004867411432076">Looi et al., 2008</xref>, <xref ref-type="bibr" rid="bibr37-0004867411432076">2009</xref>, <xref ref-type="bibr" rid="bibr39-0004867411432076">2010</xref>). In FTLD, we have identified general and specific patterns of morphological change in the neostriatum with functional implications for frontostriatal circuits (<xref ref-type="bibr" rid="bibr39-0004867411432076">Looi et al., 2010</xref>, <xref ref-type="bibr" rid="bibr38-0004867411432076">2011a</xref>). The combination of observable clinical manifestations, along with the morphology of the striatum as a biomarker of frontostriatal circuit structural integrity, constitutes a basis for a potential endophenotype. Thus FTD may, in part, be reconceptualised as a frontostriatal disorder.</p>
</sec>
<sec id="section2-0004867411432076">
<title>Current diagnostic criteria for FTLD: Limitations and challenges</title>
<p>The existing consensus criteria for FTLD focus upon clinical features of illness, and patterns of impairment (<xref ref-type="bibr" rid="bibr50-0004867411432076">Neary et al., 1998</xref>), reflecting the concept that FTLD represents a super-ordinate clinical syndrome encompassing several different neurodegenerative diseases (<xref ref-type="bibr" rid="bibr8-0004867411432076">Cairns et al., 2007</xref>), with characteristic clinical subtypes. There are three main clinical subtypes of FTLD: behavioural variant frontotemporal dementia (FTD), progressive-non-fluent aphasia (PNFA), and semantic dementia (SD). FTD is characterised by greater frontal-system dysfunction behavioural change manifest as early decline in interpersonal interaction/conduct, loss of insight and emotional blunting; SD and PNFA are believed to represent predominant temporal atrophy with specific impact upon language function (<xref ref-type="bibr" rid="bibr50-0004867411432076">Neary et al., 1998</xref>). The relationship between clinical subtype and neuropathology remains problematic, due to the fact that the same clinical features may arise from different neuropathological processes. However, there may be commonalities in the pattern of neurodegeneration which bear a closer relationship to clinical features. Neural circuit dysfunction may form a useful framework to understand such consequences of neurodegeneration. Such dysfunction would potentially be associated with specific clinical features based upon the pathways involved, and the functions they subserve. Thus, study of the neurodegeneration of structural components of neural circuits may prove fruitful in FTLD. Magnetic resonance imaging (MRI) affords a means of studying brain structure in vivo. Measurement of structural change in the brain using MRI allows potential visualisation of neurodegenerative morphological change, or at least the component manifest as atrophy, and associated changes in vivo. However, we acknowledge neurodegenerative processes may precede any identifiable morphological change, and in other instances may not manifest as morphological change.</p>
<p>To date, research in FTLD has focused on characterisation of the clinical patterns of decline and upon cortical neuropathology. Indeed, the clinical consensus criteria for FTD describe essentially behavioural changes ascribed to atrophy of frontal and temporal cortical regions. This results in a certain degree of circularity. Because the clinical features are predicated on a cortical conceptualisation of FTD, there is a selection for clinical samples that fulfil such criteria. Similarly, the macroscopic pathology and neuroimaging of FTD has focused upon focal atrophy of frontal or temporal lobes (<xref ref-type="bibr" rid="bibr57-0004867411432076">Schroeter et al., 2007</xref>), whilst microscopic pathology has focused upon the molecular pathology of neuronal loss and gliosis (<xref ref-type="bibr" rid="bibr8-0004867411432076">Cairns et al., 2007</xref>) with some neuroimaging interest in white matter disease in FTD (<xref ref-type="bibr" rid="bibr77-0004867411432076">Zhang et al., 2009</xref>), and there has been no specific investigation of subcortical structures.</p>
<p>Whilst these are necessary stages in the evolution of the understanding of FTD, it is also possible to attempt to understand FTD on the basis of distributed neural networks, in which dysfunction due to aggregation of misfolded proteins in vulnerable cell populations may result in neurodegenerative disease affecting such networks (<xref ref-type="bibr" rid="bibr59-0004867411432076">Seeley et al., 2006</xref>, <xref ref-type="bibr" rid="bibr60-0004867411432076">2008</xref>, <xref ref-type="bibr" rid="bibr61-0004867411432076">2009</xref>). In their 2008 study, Seeley et al. used voxel-based morphometry of MRI to suggest that atrophy occurred in the frontal paralimbic network in early behavioural-variant FTD, comprising associated atrophy of dorsolateral and polar frontal cortex, dorsal insula, thalamus, hippocampus and the striatum (<xref ref-type="bibr" rid="bibr60-0004867411432076">Seeley et al., 2008</xref>). Whilst such studies comprise investigation of large-scale distributed brain networks (<xref ref-type="bibr" rid="bibr48-0004867411432076">Mesulam, 2009</xref>), there exists a smaller, more constrained ensemble of circuits: the frontostriatal circuits, which are of burgeoning interest in FTD as their dysfunction may also be linked to the pattern of deficits seen in this disease group.</p>
</sec>
<sec id="section3-0004867411432076">
<title>Frontostriatal circuits and FTD: The central role of the neostriatum</title>
<p>The neostriatum is a critical relay in frontostriatal circuits, as it comprises specific re-entrant interconnections among frontal, striatal, pallidal and thalamic regions (<xref ref-type="bibr" rid="bibr1-0004867411432076">Alexander et al., 1986</xref>, <xref ref-type="bibr" rid="bibr15-0004867411432076">Draganski et al., 2008</xref>). The cognitive and behavioural abnormalities identified in FTD may be conceptualised in terms of dysfunction in frontostriatal circuits (<xref ref-type="bibr" rid="bibr23-0004867411432076">Hodges and Patterson, 2007</xref>). Frontostriatal circuits or loops include a discrete prefrontal region which sends efferent pathways through the neostriatum (caudate nucleus, putamen) or nucleus accumbens, via the globus pallidus, onto the thalamus, and thence to the back to that specific prefrontal cortex (<xref ref-type="bibr" rid="bibr1-0004867411432076">Alexander et al., 1986</xref>). These loops include motor loops originating in the frontal eye fields and supplementary motor cortex, as well as ‘cognitive loops’ arising from dorsolateral prefrontal cortex, anterior cingulate cortex and orbitofrontal cortex (<xref ref-type="bibr" rid="bibr1-0004867411432076">Alexander et al., 1986</xref>). Circuit dysfunction may result in characteristic cognitive and behavioural syndromes (<xref ref-type="bibr" rid="bibr11-0004867411432076">Cummings, 1993</xref>).</p>
<p>The dorsolateral prefrontal circuit (DLPFC), arising from Brodmann areas 9 and 10 (<xref ref-type="fig" rid="fig2-0004867411432076">Figure 2</xref>), mediates problem solving, verbal/non-verbal fluency and retrieval from memory, and is linked to the limbic memory system. Clinical syndromes associated with DLPFC dysfunction are described as executive dysfunction and are characterised by deficits in cognition related to the above domains (<xref ref-type="bibr" rid="bibr11-0004867411432076">Cummings, 1993</xref>; <xref ref-type="bibr" rid="bibr30-0004867411432076">Koziol and Budding, 2009</xref>). The orbitofrontal circuit (OFC), arising from Brodmann areas 10 and 11 (<xref ref-type="fig" rid="fig3-0004867411432076">Figure 3</xref>), mediates inhibition and impulse control. Clinical syndromes associated with OFC dysfunction are described as emotional and social dysfunction and are characterised by deficits in social judgement and impulse control (<xref ref-type="bibr" rid="bibr11-0004867411432076">Cummings, 1993</xref>; <xref ref-type="bibr" rid="bibr30-0004867411432076">Koziol and Budding, 2009</xref>). Recently, subdivisions of the OFC into lateral and medial portions have been described, with lateral Brodmann areas 10 and 11 connecting to ventromedial caudate, and medial Brodmann area 11 connecting to the nucleus accumbens (<xref ref-type="bibr" rid="bibr63-0004867411432076">Tekin and Cummings, 2002</xref>). The anterior cingulate (or ventromedial prefrontal) circuit (ACC), arising from Brodmann area 24 (<xref ref-type="fig" rid="fig4-0004867411432076">Figure 4</xref>), mediates motivation and initiation of behaviour. Clinical syndromes associated with ACC dysfunction are described as apathy and loss of motivation, including akinetic mutism, and are characterised by lack of motivation (<xref ref-type="bibr" rid="bibr11-0004867411432076">Cummings, 1993</xref>; <xref ref-type="bibr" rid="bibr30-0004867411432076">Koziol and Budding, 2009</xref>). Therefore, syndromes associated with frontostriatal circuit dysfunctions are consistent with many of the clinical manifestations of FTD.</p>
<fig id="fig2-0004867411432076" position="float">
<label>Figure 2.</label>
<caption><p>Dorsolateral prefrontal cortex circuit.</p>
<p>DLPFC: dorsolateral prefrontal cortex</p>
<p>GP: globus pallidus</p>
<p>SN: substantia nigra</p></caption>
<graphic xlink:href="10.1177_0004867411432076-fig2.tif"/>
</fig>
<fig id="fig3-0004867411432076" position="float">
<label>Figure 3.</label>
<caption><p>Orbitofrontal cortex circuit.</p>
<p>OFC: orbitofrontal cortex</p>
<p>GP: globus pallidus</p>
<p>SN: substantia nigra</p></caption>
<graphic xlink:href="10.1177_0004867411432076-fig3.tif"/>
</fig>
<fig id="fig4-0004867411432076" position="float">
<label>Figure 4.</label>
<caption><p>Anterior cingulate cortex circuit.</p>
<p>ACC: anterior cingulate cortex</p>
<p>GP: globus pallidus</p>
<p>SN: substantia nigra</p></caption>
<graphic xlink:href="10.1177_0004867411432076-fig4.tif"/>
</fig>
<p>Cognitive and behavioural dysfunction mediated via frontostriatal circuits in FTD may be reflected in structural change in components of that circuitry (<xref ref-type="bibr" rid="bibr39-0004867411432076">Looi et al., 2010</xref>). A meta-analysis of both structural and functional imaging of FTLD and controls demonstrated the existence of characteristic patterns of activation and atrophy for each of the subtypes of FTLD in: prefrontal cortex, temporal lobe, amygdala and neostriatum (<xref ref-type="bibr" rid="bibr57-0004867411432076">Schroeter et al., 2007</xref>). Whilst FTLD has traditionally been considered to result from disease of the frontal or temporal cortex, the neostriatum itself may also be involved. The same neuropathological processes that affect the frontal and temporal cortex may also affect the neostriatum. There may be secondary neuroplastic changes due to trans-synaptic neurodegeneration arising from frontal or temporal pathology, or indeed pallido-thalamic pathology. Finally, the neostriatum has particular vulnerability to hypoxic, metabolic and vascular disease as a result of a limited vascular supply arising primarily from perforating terminal vessels from the circle of Willis.</p>
<p>The neostriatum serves as an entry point for afferent information from the periphery, as well as for afferents and efferents for functionally segregated regions of the cortex (<xref ref-type="bibr" rid="bibr1-0004867411432076">Alexander et al., 1986</xref>; <xref ref-type="bibr" rid="bibr20-0004867411432076">Haber, 2003</xref>; <xref ref-type="bibr" rid="bibr21-0004867411432076">Haber et al., 2000</xref>). Grey matter volumes in intrinsic neural connectivity networks have been correlated with function in healthy controls (<xref ref-type="bibr" rid="bibr61-0004867411432076">Seeley et al., 2009</xref>), and the neostriatum comprises a significant subcortical grey matter body. The corollary is that cortical atrophy may lead to loss of inputs to the neostriatum and neuroplastic reduction in the grey matter volume of the neostriatum. Similarly, there is evidence of deep white matter pathology between the frontal lobes and the neostriatum (<xref ref-type="bibr" rid="bibr2-0004867411432076">Avants et al., 2010</xref>; <xref ref-type="bibr" rid="bibr71-0004867411432076">Whitwell et al., 2010</xref>; <xref ref-type="bibr" rid="bibr77-0004867411432076">Zhang et al., 2009</xref>), which may result in disconnection or diaschisis of frontostriatal circuits, with associated neuroplastic change in the neostriatum. It is possible that these white matter changes may arise from altered neuronal function in the white matter itself. Alternatively, the white matter disease may arise from secondary neuroplastic change due to cortical changes, and/or changes in other components of the circuits, such as the striatum, pallidum and thalamus.</p>
</sec>
<sec id="section4-0004867411432076">
<title>Clinical syndromes of FTLD: Relationship to frontostriatal circuits</title>
<p>As they are presently constituted, the clinical subtypes of FTLD arguably cluster clinical features that may have a structural basis in the smaller-scale distributed neural networks of the frontostriatal circuits.</p>
<p>There have been attempts to differentiate the clinical subtypes of FTLD based upon neurobehavioural features and neuropsychological testing (<xref ref-type="bibr" rid="bibr5-0004867411432076">Bozoki and Farooq, 2009</xref>). The clearest distinction is between FTD and the two language-disordered subtypes, PNFA and SD, in terms of behaviour. Clinically, FTD displays greater degrees of neurobehavioural disturbance, in the form of pathological behaviours, than either PNFA or SD (<xref ref-type="bibr" rid="bibr5-0004867411432076">Bozoki and Farooq, 2009</xref>). That is, FTD patients display greater apathy, disinhibition, aberrant motor behaviour, eating disorder and agitation as assessed via the Neuropsychiatric Inventory (<xref ref-type="bibr" rid="bibr5-0004867411432076">Bozoki and Farooq, 2009</xref>; <xref ref-type="bibr" rid="bibr46-0004867411432076">Marra et al., 2007</xref>; <xref ref-type="bibr" rid="bibr54-0004867411432076">Rankin et al., 2006</xref>; <xref ref-type="bibr" rid="bibr56-0004867411432076">Rosen et al., 2006</xref>). Motivation is ascribed to a structural substrate in the anterior cingulate frontostriatal circuit (<xref ref-type="bibr" rid="bibr11-0004867411432076">Cummings, 1993</xref>), thus the apathy seen in FTD may be due to dysfunction of this circuit. Similarly, maintenance of social comportment, and inhibition of disordered behaviours, has a structural basis in the orbitofrontal circuit; thus disinhibition, agitation and eating disorder may reflect dysfunction of this circuit (<xref ref-type="bibr" rid="bibr11-0004867411432076">Cummings, 1993</xref>). Recently, there has been literature linking behavioural changes with their presumed substrates, such as the finding that right caudate/subcallosal gyrus grey matter density was correlated with empathy (<xref ref-type="bibr" rid="bibr54-0004867411432076">Rankin et al., 2006</xref>). Aberrant motor behaviours in FTD may be associated with downstream dysfunction of the common putaminal component of a number of frontostriatal circuits (<xref ref-type="bibr" rid="bibr28-0004867411432076">Josephs et al., 2008</xref>; <xref ref-type="bibr" rid="bibr39-0004867411432076">Looi et al., 2010</xref>). Therefore, the neostriatum, as a component of frontostriatal circuits, may be a potential structural basis for FTD behavioural manifestations.</p>
<p>In addition, there is evidence of relatively more impairment on executive tasks in FTD compared to controls, and other neurodegenerative disease (<xref ref-type="bibr" rid="bibr75-0004867411432076">Wittenberg et al., 2008</xref>). Such functions, such as planning, sequencing, verbal fluency, set-shifting and mental flexibility; are also served by primarily dorsolateral prefrontal frontostriatal circuits (<xref ref-type="bibr" rid="bibr1-0004867411432076">Alexander et al., 1986</xref>; <xref ref-type="bibr" rid="bibr11-0004867411432076">Cummings, 1993</xref>). In contrast, language impairments are more common in SD and PNFA, [soon to be reclassified as primary progressive aphasia, fluent and non-fluent (<xref ref-type="bibr" rid="bibr75-0004867411432076">Wittenberg et al., 2008</xref>)], implicating temporal lobe structures and circuits other than frontostriatal.</p>
<p>However, there is evidence that, as PNFA progresses, the behavioural presentation ultimately resembles that of FTD (<xref ref-type="bibr" rid="bibr4-0004867411432076">Banks and Weintraub, 2008</xref>; <xref ref-type="bibr" rid="bibr5-0004867411432076">Bozoki and Farooq, 2009</xref>; <xref ref-type="bibr" rid="bibr45-0004867411432076">Marczinski et al., 2004</xref>). The corollary is that, relative to SD, PNFA may manifest behavioural disorders secondary to frontostriatal circuit dysfunction involving the neostriatum, albeit to a lesser degree and of later onset than FTD. SD patients show lesser degrees of behavioural change, such as interruptive behaviour, perseveration, tangentiality and resisted redirection (<xref ref-type="bibr" rid="bibr55-0004867411432076">Rankin et al., 2008</xref>).</p>
<p>Furthermore, a large longitudinal study of patients with several subtypes of FTLD showed persistent group differences on neuropsychological testing, with the caveat that there was a restricted range of tests included for the large sample (<xref ref-type="bibr" rid="bibr33-0004867411432076">Libon et al., 2009</xref>). Allowing for the classification of the behavioural variant FTD by Libon et al. into an analogous SOC/EXEC impairment group, both the FTD and PNFA groups show a predominant executive dysfunction, compared to contrasting differences for SD on confrontational naming (<xref ref-type="bibr" rid="bibr33-0004867411432076">Libon et al., 2009</xref>). Interestingly, this group states the executive dysfunction in PNFA may, in fact, be greater than in the FTD subtype.</p>
<p>The relevance of frontostriatal circuit or networks in the cognitive and behavioural presentation of FTLD has been increasingly recognised, and is the focus of ongoing investigation (<xref ref-type="bibr" rid="bibr53-0004867411432076">Rabinovici et al., 2007</xref>; <xref ref-type="bibr" rid="bibr75-0004867411432076">Wittenberg et al., 2008</xref>). Interestingly, homology of the neuropsychological profile of the behavioural variant FTD, the subtype with greatest executive dysfunction, has been found with Lewy body dementia, a neurodegenerative disorder significantly affecting the striatal system (<xref ref-type="bibr" rid="bibr27-0004867411432076">Johns et al., 2009</xref>). As many of these pathways are routed through the neostriatum, this structure may provide a strategic view of the neuroanatomical basis of such presentations.</p>
</sec>
<sec id="section5-0004867411432076">
<title>The neostriatum in FTLD: Neuropathological findings</title>
<p>Severe atrophy of the caudate and putamen was noted long ago in FTLD via post-mortem studies (<xref ref-type="bibr" rid="bibr68-0004867411432076">von Braunmühl, 1930</xref>). Macroscopic neuropathology reveals that atrophy of basal ganglia is seen in a proportion of cases (<xref ref-type="bibr" rid="bibr8-0004867411432076">Cairns et al., 2007</xref>), with the caveat that it may be difficult to detect mild striatal atrophy post-mortem (E. Englund, 2010, personal communication). Recent neuropathological studies have shown that early and specific neurodegeneration occurs in the striatum (<xref ref-type="bibr" rid="bibr53-0004867411432076">Rabinovici et al., 2007</xref>; <xref ref-type="bibr" rid="bibr72-0004867411432076">Whitwell et al., 2009a</xref>).</p>
<p>Overall, there is not a precise correspondence between the clinical syndromes and the identified molecular neuropathology in FTLD (<xref ref-type="bibr" rid="bibr7-0004867411432076">Burrell and Hodges, 2010</xref>; <xref ref-type="bibr" rid="bibr41-0004867411432076">Macedo et al., 2009</xref>). <xref ref-type="bibr" rid="bibr41-0004867411432076">Macedo and colleagues (2009)</xref> have classified the molecular neuropathology corresponding to the overall macroscopic frontotemporal lobar presentation. Behavioural variant FTD has been associated with tau and TAR DNA-binding protein (TDP-43) molecular pathology. Of the tau-predominant pathologies, PNFA is often associated with clinical presentations of progressive supranuclear palsy (PSP) and corticobasal syndrome/degeneration (CBD). In SD, considered due to predominant left temporal atrophy, there may be tau, Pick bodies and Alzheimer’s disease pathology (up to 20%). <xref ref-type="bibr" rid="bibr41-0004867411432076">Macedo et al. (2009)</xref> also describe a right temporal lobe variant with TDP-43, Pick bodies and Alzheimer’s disease pathology in up to 20%. For ease of reference we have reproduced a version of a table that summarises the most recent molecular neuropathological findings for the major FTLD subtypes: FTD, SD and PNFA (<xref ref-type="bibr" rid="bibr7-0004867411432076">Burrell and Hodges, 2010</xref>; <xref ref-type="bibr" rid="bibr52-0004867411432076">Rabinovici and Miller, 2010</xref>) (<xref ref-type="table" rid="table1-0004867411432076">Table 1</xref>).</p>
<table-wrap id="table1-0004867411432076" position="float">
<label>Table 1.</label>
<caption><p>FTLD subtype by molecular pathology</p></caption>
<graphic alternate-form-of="table1-0004867411432076" xlink:href="10.1177_0004867411432076-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th/>
<th align="left">Tau</th>
<th align="left">TDP-43</th>
<th align="left">FUS</th>
</tr>
</thead>
<tbody>
<tr>
<td><bold>FTD</bold></td>
<td>45%</td>
<td>45%</td>
<td>5%</td>
</tr>
<tr>
<td><bold>PNFA</bold></td>
<td>70%</td>
<td>30%</td>
<td>?</td>
</tr>
<tr>
<td><bold>SD</bold></td>
<td>90%</td>
<td>10%</td>
<td>?</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0004867411432076">
<p>Tau, microtubule associated tau protein; TDP-43, TAR DNA binding protein 43; FUS, fused in sarcoma; FTD, frontotemporal dementia; PNFA, progressive non-fluent aphasia; SD, semantic dementia.</p></fn>
<fn id="table-fn2-0004867411432076">
<p>Modified from <xref ref-type="bibr" rid="bibr7-0004867411432076">Burrell and Hodges (2010)</xref>.</p></fn>
</table-wrap-foot>
</table-wrap>
<p>The most common molecular pathological changes in FTLD are tau-negative, ubiquitin-immunoreactive intraneuronal inclusions that frequently stain positive for TDP-43 and are often associated with mutations in the progranulin (PGRN) gene (FTLD-TDP). FTLD-TDP may preferentially affect cortical regions and hippocampus, but also shows striatal atrophy.</p>
<p>The next most common neuropathological change is FTLD-tau, known as Pick’s disease. Pick bodies are found in neocortex, subiculum, hippocampus, entorhinal cortex and subcortical (including striatal) regions (<xref ref-type="bibr" rid="bibr51-0004867411432076">Neumann et al., 2009</xref>). In the other tauopathy-associated subtypes of PNFA, progressive supranuclear palsy and corticobasal degeneration, tau accumulation is prominent in striatal regions (<xref ref-type="bibr" rid="bibr8-0004867411432076">Cairns et al., 2007</xref>).</p>
<p>Previously identified as the ubiquitin-positive, tau- negative FTLD, FTLD-FUS (fused in sarcoma) is associated with amyotrophic lateral sclerosis (ALS) and shows marked striatal neurite damage and atrophy (<xref ref-type="bibr" rid="bibr43-0004867411432076">Mackenzie and Rademakers, 2007</xref>; <xref ref-type="bibr" rid="bibr42-0004867411432076">Mackenzie et al., 2006</xref>; <xref ref-type="bibr" rid="bibr51-0004867411432076">Neumann et al., 2009</xref>). An earlier age of onset and more rapid decline has been found in FTLD-FUS, as has marked striatal atrophy (<xref ref-type="bibr" rid="bibr13-0004867411432076">Davion et al., 2007</xref>; <xref ref-type="bibr" rid="bibr31-0004867411432076">Leverenz et al., 2007</xref>), and is associated with asymmetric motor disturbance (<xref ref-type="bibr" rid="bibr76-0004867411432076">Yokota et al., 2009</xref>). Extreme atrophy of the caudate has been observed at autopsy and ante-mortem in FTLD-FUS (<xref ref-type="bibr" rid="bibr29-0004867411432076">Josephs et al., 2010</xref>).</p>
<p>Frontotemporal dementia with motor neuron disease (FTD-MND) also shows marked striatal atrophy (<xref ref-type="bibr" rid="bibr58-0004867411432076">Seelaar et al., 2007</xref>). On VBM of MRI, patients with mutations in the microtubule-associated protein tau (MAPT) showed greater putaminal atrophy than those with the PGRN mutation (<xref ref-type="bibr" rid="bibr73-0004867411432076">Whitwell et al., 2009b</xref>). In FTD and Parkinsonism linked to chromosome 17 associated with the tau gene mutations (FTDP-17T), macroscopic atrophy is detectable at the intermediate stage in the caudate nucleus, whilst caudate and putaminal atrophy may be more evident in advanced illness (<xref ref-type="bibr" rid="bibr18-0004867411432076">Ghetti et al., 2003</xref>).</p>
<p>Thus, aside from the cortical neuropathology associated with the molecular subtypes of FTLD, there is convergent evidence of involvement of the striatum, which may be as a result of the particular strategic susceptibility of this structure to metabolic, hypoxic or vascular disease (I. Mackenzie, 2010, personal communication). This sensitivity of the striatum as a potential marker is operationalised in the consensus algorithms for neuropathological diagnosis of FTLD, which involve staining and investigation of the striatum (<xref ref-type="bibr" rid="bibr8-0004867411432076">Cairns et al., 2007</xref>).</p>
<p>There has been evidence that other neuropathological processes may affect the neostriatum, such as beta-amyloid deposition in Alzheimer’s disease (<xref ref-type="bibr" rid="bibr67-0004867411432076">Villemagne et al., 2009</xref>), and accordingly there may be considerable overlap in the accumulation of neurodegenerative burden. This may be illustrated in behavioural phenocopy conditions such as progressive logopenic aphasia, which clinically presents with features in common with SD/PNFA, but which arises primarily from AD pathology (<xref ref-type="bibr" rid="bibr19-0004867411432076">Gorno-Tempini et al., 2008</xref>). Beta-amyloid deposition has also been described in clinical FTD cases, confirming the possibility of overlap in molecular pathology (<xref ref-type="bibr" rid="bibr25-0004867411432076">Hu et al., 2011</xref>). The specific vulnerability of the morphology of the neostriatum to parallel disease processes may be a sensitive marker of disease, correlation of which to clinical features and molecular pathology may yield insights into the relative contributions of various neurodegenerative processes.</p>
</sec>
<sec id="section6-0004867411432076">
<title>Neurochemical CSF studies of FTLD</title>
<p>In vivo CSF studies have focused on the role of biomarker analysis, and some studies have identified that FTLD subtypes differ from AD and each other in CSF biomarkers (<xref ref-type="bibr" rid="bibr24-0004867411432076">Hu et al., 2010</xref>), although there remain a profusion of candidate biochemical markers, the relative roles of which remain uncertain (<xref ref-type="bibr" rid="bibr25-0004867411432076">Hu et al., 2011</xref>). AD may be distinguished from FTLD by p-tau<sub>181</sub> (rather than total tau), Aβ<sub>42</sub>, and agouti-related peptide (AgRP); whilst the FTLD-tau neuropathological subtype may potentially be distinguished from FTLD-TDP by adrenocorticotropic hormone (ACTH), eotaxin-3, Fas, and interleukin 17 (IL-17) (<xref ref-type="bibr" rid="bibr24-0004867411432076">Hu et al., 2010</xref>). Neither Aβ<sub>42</sub> or, surprisingly, CSF tau differed between FTLD-tau or FTD-TDP (<xref ref-type="bibr" rid="bibr24-0004867411432076">Hu et al., 2010</xref>). At this stage, these CSF biomarkers require further validation, although their presence, combined with the neuropathological findings discussed above, supports the view that there may be a convergence of neurodegenerative processes in FTLD, some of which may localise to the neostriatum. There is a potential role for multiple biomarker cross-validation, including: genotype, molecular pathology, neuropathology, CSF analytes, neuroimaging, gross neuroanatomy and clinical features; through the striatum.</p>
</sec>
<sec id="section7-0004867411432076">
<title>Neuroimaging of the neostriatum in FTD</title>
<p>Our recent neuroimaging research (<xref ref-type="bibr" rid="bibr35-0004867411432076">Looi et al., 2008</xref>, <xref ref-type="bibr" rid="bibr37-0004867411432076">2009</xref>) and that of others (<xref ref-type="bibr" rid="bibr10-0004867411432076">Chow et al., 2008</xref>; <xref ref-type="bibr" rid="bibr17-0004867411432076">Garibotto et al., 2011</xref>) has identified that subcortical atrophy in the neostriatum (caudate nucleus and putamen) may be a crucial factor underlying the cognitive, emotional and behavioural decline of FTD in vivo. Furthermore, this striatal atrophy has been demonstrated using methodologically distinct MRI analysis methods: manual segmentation (<xref ref-type="bibr" rid="bibr35-0004867411432076">Looi et al., 2008</xref>, <xref ref-type="bibr" rid="bibr37-0004867411432076">2009</xref>), automated parcellation (<xref ref-type="bibr" rid="bibr10-0004867411432076">Chow et al., 2008</xref>) and probabilistic mapping (<xref ref-type="bibr" rid="bibr17-0004867411432076">Garibotto et al., 2011</xref>). These in vivo neuroimaging findings converge with recent neuropathological studies demonstrating that specific intraneuronal inclusions and atrophy are present in the neostriatum, especially in younger-onset familial forms of FTLD (<xref ref-type="bibr" rid="bibr13-0004867411432076">Davion et al., 2007</xref>; <xref ref-type="bibr" rid="bibr31-0004867411432076">Leverenz et al., 2007</xref>; <xref ref-type="bibr" rid="bibr58-0004867411432076">Seelaar et al., 2007</xref>), in autopsy-confirmed FTLD (<xref ref-type="bibr" rid="bibr53-0004867411432076">Rabinovici et al., 2007</xref>, <xref ref-type="bibr" rid="bibr72-0004867411432076">Whitwell et al., 2009a</xref>); and with evidence of associated circuit atrophy, present in early clinically diagnosed FTD (<xref ref-type="bibr" rid="bibr60-0004867411432076">Seeley et al., 2008</xref>).</p>
<p>Recently, correlations between cortical thickness and white matter integrity measured using diffusion tensor imaging have been found in FTLD, demonstrating patterns distinguishing AD and FTLD, with greater white matter disease in the genu of the corpus callosum, left uncinate, left inferior fronto-occipital fasciciulus, cingulum and bilateral corona radiata being linked to cortical changes in anterior cingulate, middle, inferior and orbitofrontal gyri (<xref ref-type="bibr" rid="bibr2-0004867411432076">Avants et al., 2010</xref>). Of these structures, the cingulate and frontal gyri of the cortex, as well as the cingulum and corona radiata, may have interconnections to the neostriatum. Through either secondary neuroplastic (trans-synaptic neurodegeneration) or shared neurodegenerative processes the neostriatum may also be affected. Similarly, there has been evidence of increased mean diffusivity, and hence reduced structural integrity of grey matter in frontal and temporal regions in FTLD, associated with mean diffusivity changes in white matter tracts to the frontal lobes (<xref ref-type="bibr" rid="bibr71-0004867411432076">Whitwell et al., 2010</xref>). Again, this implies a possible role for altered structural integrity of white and grey matter in FTLD impacting upon the neostriatum.</p>
<p>Therefore, striatal atrophy may be an early and sensitive biomarker for FTD, especially in the younger-onset familial forms of FTD. Similarly, since early specific neuropathology is present in the neostriatum in FTD, there is potential that neostriatal atrophy may be a biomarker for preclinical FTD, as has been proposed in Huntington’s disease (<xref ref-type="bibr" rid="bibr3-0004867411432076">Aylward, 2007</xref>). Thus, there is convergent evidence that structural change may arise in the neostriatum due to both neuronal level molecular pathological neurodegeneration and frontostriatal circuit nodal morphological change in white or grey matter. As these findings converge upon the neostriatum, so the neostriatum may prove to be a sentinel marker for early FTD.</p>
</sec>
<sec id="section8-0004867411432076">
<title>Neostriatal atrophy in subtypes of FTLD</title>
<p>We hypothesised that frontostriatal neurodegeneration may be the structural basis of clinical manifestations of FTLD, and found that significant neostriatal atrophy was evident in FTLD, but not in controls or Alzheimer’s disease (<xref ref-type="bibr" rid="bibr35-0004867411432076">Looi et al., 2008</xref>, <xref ref-type="bibr" rid="bibr37-0004867411432076">2009</xref>). Independently, <xref ref-type="bibr" rid="bibr53-0004867411432076">Rabinovici et al. (2007)</xref> concluded that, in their autopsy-confirmed group with FTLD, there was evidence of degeneration in the frontostriatal network in FTLD in comparison with Alzheimer’s disease, with specific atrophy in the anterior cingulate, frontal insula, subcallosal gyrus and striatum in FTLD.</p>
<p>There is also converging evidence that the behavioural variant FTD is associated with greater neostriatal atrophy than other subtypes of FTLD, as might be expected based upon the observation the clinical phenotype of FTD is essentially that of frontostriatal dysfunction. Our study showed there was a gradient in severity of atrophy, such that FTD showed more atrophy than PNFA and SD (<xref ref-type="bibr" rid="bibr35-0004867411432076">Looi et al., 2008</xref>). <xref ref-type="bibr" rid="bibr10-0004867411432076">Chow et al. (2008)</xref> demonstrated specific striatal atrophy in FTD, whilst <xref ref-type="bibr" rid="bibr17-0004867411432076">Garibotto et al. (2011)</xref> demonstrated bilateral striatal atrophy in FTD. Using VBM, <xref ref-type="bibr" rid="bibr61-0004867411432076">Seeley et al. (2009)</xref> demonstrated syndrome-specific regional atrophy in FTLD subtypes, finding specific atrophy in the striatum in FTD, and our interpretation of their atrophy patterns suggests involvement of striatum in both SD and PNFA. Also using VBM, <xref ref-type="bibr" rid="bibr73-0004867411432076">Whitwell et al. (2009b</xref>,<xref ref-type="bibr" rid="bibr74-0004867411432076">c)</xref> studied ‘subtypes’ of FTD, classifying into four groups based on the relative lobar atrophy: temporal dominant, temporo-fronto-parietal, frontotemporal and frontal dominant. Both frontotemporal and frontal dominant subgroups of FTD showed atrophy of the caudate nucleus, and in the putamen in the frontotemporal group. Thus, there is evidence that neostriatal degeneration may be both specific to FTLD in comparison with Alzheimer’s disease, and be more prominent in subtypes with greater frontostriatal dysfunction, such as FTD, rather than PNFA or SD.</p>
</sec>
<sec id="section9-0004867411432076">
<title>Towards a frontostriatal endophenotype for FTD</title>
<p>The concept of an endophenotype has been employed to investigate neuropsychiatric disease, such as FTLD: that is, a restricted set of phenotypic or clinical features that may have a more specific structural and hence, genetic basis (<xref ref-type="bibr" rid="bibr70-0004867411432076">Weiser et al., 2005</xref>). An example of an endophenotype is frontal-executive neuropsychological function, localised to the neural substrate of dorsolateral prefrontal cortex frontostriatal circuit, which has been investigated fruitfully in schizophrenia. Consequently, it is possible to explore the structural basis of an endophenotype by studying the components of neural circuits carrying such functions. As the frontostriatal circuits that traverse the neostriatum serve specific cognitive, emotional and behavioural functions which can be assessed via neuropsychological testing, clinical scales and observations, the combination of the neostriatal biomarker and clinical features constitutes a potential frontostriatal endophenotype.</p>
<p>Regional morphological change, in addition to volumetric change, in the neostriatum may allow us to quantify the neurostructural basis of the frontostriatal endophenotype in FTD. Neostriatal components are ideal candidate structures for morphological or shape analysis due to the highly specific nature of their regional interconnections. Thus, morphological analysis (<xref ref-type="bibr" rid="bibr64-0004867411432076">Thompson, 1945</xref>) may be a useful tool to quantify neurodegenerative atrophy, manifest as shape change in FTD.</p>
</sec>
<sec id="section10-0004867411432076">
<title>Morphology of the neostriatum as a map of frontostriatal circuit neurodegeneration</title>
<p>The caudate and putamen are divided into highly specific functional subregions based on afferents received from the frontal cortex and substantia nigra (<xref ref-type="bibr" rid="bibr20-0004867411432076">Haber, 2003</xref>; <xref ref-type="bibr" rid="bibr21-0004867411432076">Haber et al., 2000</xref>). The caudate head and body receives connections on its lateral aspect from the dorsolateral prefrontal cortex, inferior orbitofrontal cortex, and posterior parietal cortex, whereas the tail receives input from the frontal eye fields. On its medial aspect, the caudate is connected to the anterior cingulate cortex (<xref ref-type="bibr" rid="bibr1-0004867411432076">Alexander et al., 1986</xref>; <xref ref-type="bibr" rid="bibr21-0004867411432076">Haber et al., 2000</xref>; <xref ref-type="bibr" rid="bibr22-0004867411432076">Heimer and Van Hoesen, 2006</xref>; <xref ref-type="bibr" rid="bibr66-0004867411432076">Utter and Basso, 2008</xref>). The putamen receives connections on its medial aspect from the motor cortex, and somatosensory cortex. The lateral putamen receives connections from the supplementary motor area. <xref ref-type="bibr" rid="bibr21-0004867411432076">Haber et al. (2000)</xref> and <xref ref-type="bibr" rid="bibr20-0004867411432076">Haber (2003)</xref> also described connections from the dorsolateral prefrontal cortex to the ventral aspect of the putamen. In addition, there are fibres traversing the internal capsule linking the caudate and putamen above their mutual origin in the nucleus accumbens (<xref ref-type="bibr" rid="bibr1-0004867411432076">Alexander et al., 1986</xref>; <xref ref-type="bibr" rid="bibr15-0004867411432076">Draganski et al., 2008</xref>; <xref ref-type="bibr" rid="bibr22-0004867411432076">Heimer and Van Hoesen, 2006</xref>; <xref ref-type="bibr" rid="bibr66-0004867411432076">Utter and Basso, 2008</xref>). Regional changes in the shape of the caudate and putamen may thus be associated with dysfunction of specific circuits with resultant clinical consequences (<xref ref-type="fig" rid="fig5-0004867411432076">Figures 5</xref> and <xref ref-type="fig" rid="fig6-0004867411432076">6</xref>).</p>
<fig id="fig5-0004867411432076" position="float">
<label>Figure 5.</label>
<caption><p>Diagram demonstrating the functional organisation of the frontal cortex and striatal afferent projections. (A) Schematic illustration of the functional connections linking frontal cortical brain regions. (B) Organisation of cortical and subcortical inputs to the striatum. In both (A) and (B), the colours denote functional distinctions. Blue: motor cortex, execution of motor actions; green: pre-motor cortex, planning of movements; yellow: dorsal and lateral prefrontal cortex, cognitive and executive functions; orange: orbital prefrontal cortex, goal-directed behaviours and motivation; red: medial prefrontal cortex, goal-directed behaviours and emotional processing.</p>
<p>(Figure reproduced from <xref ref-type="bibr" rid="bibr20-0004867411432076">Haber, 2003</xref>, with permission)</p></caption>
<graphic xlink:href="10.1177_0004867411432076-fig5.tif"/>
</fig>
<fig id="fig6-0004867411432076" position="float">
<label>Figure 6.</label>
<caption><p>Map of striatal afferents.</p>
<p>(Reproduced from <xref ref-type="bibr" rid="bibr36-0004867411432076">Looi et al., 2011b</xref>, with permission)</p></caption>
<graphic xlink:href="10.1177_0004867411432076-fig6.tif"/>
</fig>
<p>Spherical harmonic shape analysis (SPHARM) of the caudate and putamen is able to resolve localised areas of morphological change. <xref ref-type="bibr" rid="bibr32-0004867411432076">Levitt et al. (2009)</xref>, <xref ref-type="bibr" rid="bibr62-0004867411432076">Styner et al. (2006)</xref>, <xref ref-type="bibr" rid="bibr26-0004867411432076">Hwang et al. (2006)</xref>, <xref ref-type="bibr" rid="bibr9-0004867411432076">Choi et al. (2007)</xref> and <xref ref-type="bibr" rid="bibr44-0004867411432076">Mamah et al. (2008)</xref> have previously applied shape analysis to the striatum in schizotypal personality disorder, bipolar disorder, obsessive–compulsive disorder and siblings of persons with schizophrenia, respectively. <xref ref-type="bibr" rid="bibr32-0004867411432076">Levitt et al. (2009)</xref> found an association between shape deflation and verbal learning capacity in females with schizotypal personality disorder, implicating frontostriatal connections to the ventromedial prefrontal cortex. We have applied shape analysis to the congenital genetic disorder choreoacanthocytosis (ChAc) with significant findings of neostriatal shape and volume change compared to controls (<xref ref-type="bibr" rid="bibr69-0004867411432076">Walterfang et al., 2011</xref>). As ChAc is a specific genetic disorder, resulting in isolated atrophy of the neostriatum, this supports the case for frontostriatal circuits as a potential structural basis for the endophenotype of obsessive–compulsive phenomena and frontal-executive dysfunction seen in ChAc. Furthermore, we found altered striatal morphology in progressive supranuclear palsy, a Parkinson’s plus syndrome in which abnormal tau accumulates in the striatum, in association with a dysexecutive syndrome, apathy and other frontostriatal system clinical features (<xref ref-type="bibr" rid="bibr36-0004867411432076">Looi et al., 2011b</xref>). Similarly, the frontostriatal endophenotype is relevant for FTLD.</p>
<p>Using SPHARM, we investigated the shape of the neostriatum as a map of regional atrophy in relevant frontostriatal circuits in FTLD, AD and controls (<xref ref-type="bibr" rid="bibr39-0004867411432076">Looi et al., 2010</xref>, <xref ref-type="bibr" rid="bibr38-0004867411432076">2011a</xref>, finding that there are regionally specific shape deflations in the neostriatum, and thus potential neural substrates for a frontostriatal endophenotype in FTLD. We have also found that the neostriatal shape and volume differences in subtypes of FTLD such as behavioural variant FTD, SD and PNFA correspond with the expected degree of frontostriatal dysfunction, with greatest atrophy seen in FTD, followed by PNFA and SD (<xref ref-type="bibr" rid="bibr35-0004867411432076">Looi et al., 2008</xref>, <xref ref-type="bibr" rid="bibr37-0004867411432076">2009</xref>). Therefore, the neostriatum may also be a biomarker useful for subtyping or, more specifically, endophenotyping of FTLD.</p>
</sec>
<sec id="section11-0004867411432076">
<title>Patterns of morphological change in FTLD and neurodegeneration</title>
<p>In our shape analyses of FTLD and subtypes, we found there was significant shape and volume difference between 34 patients with FTLD, 19 patients with Alzheimer’s disease (AD) and 27 controls (<xref ref-type="bibr" rid="bibr39-0004867411432076">Looi et al., 2010</xref>, <xref ref-type="bibr" rid="bibr38-0004867411432076">2011a</xref>). When all FTLD subtypes were combined, there was significant shape deflation in the left caudate compared to AD, and bilaterally compared to controls, with significant but lesser changes in the putamen (<xref ref-type="bibr" rid="bibr39-0004867411432076">Looi et al., 2010</xref>). When we investigated the FTLD subtypes, we found that the FTD subtype appeared to be the main contributor to the shape deflation in the caudate, followed by PNFA and minimal change in the SD subgroup; and again, lesser changes in the putamen, compared to controls (<xref ref-type="bibr" rid="bibr38-0004867411432076">Looi et al., 2011a</xref>).</p>
<p>Our shape analysis identified both general and specific patterns of shape deflation with FTLD (<xref ref-type="bibr" rid="bibr39-0004867411432076">Looi et al., 2010</xref>, <xref ref-type="bibr" rid="bibr38-0004867411432076">2011a</xref>). The pattern of shape deflation may correspond to distance from sources of neurogenesis for the caudate. There are at least two regions adjacent to or within the caudate in which neurogenesis may occur: the shell of the nucleus accumbens (<xref ref-type="bibr" rid="bibr22-0004867411432076">Heimer and Van Hoesen, 2006</xref>), and the subventricular zone comprising the medial border of the caudate (<xref ref-type="bibr" rid="bibr12-0004867411432076">Curtis et al., 2007</xref>). We hypothesised that distance from neurogenic zones may influence the rate and extent of reactive neurogenesis in response to neurodegeneration, analogous to the pattern of morphogenesis observed with chemical gradients in living organisms (<xref ref-type="bibr" rid="bibr64-0004867411432076">Thompson, 1945</xref>; <xref ref-type="bibr" rid="bibr65-0004867411432076">Turing, 1952</xref>). That is, the more distant the surface of the structure from a neurogenic source, the less likely it is to receive new neurons, and thus the more likely it is to show atrophy, manifest as shape deflation in a gradient notionally inversely proportional to the distance from the source. We observed two gradients of atrophy in the caudate in FTLD consistent with the distance from a neurogenic origin in the nucleus accumbens: dorsal–ventral and posterior–anterior. A dorsal–ventral gradient of atrophy has also been described in other neurodegenerative disease affecting the caudate and putamen: Huntington’s disease (<xref ref-type="bibr" rid="bibr14-0004867411432076">Douaud et al., 2006</xref>) and choreoacanthocytosis (<xref ref-type="bibr" rid="bibr69-0004867411432076">Walterfang et al., 2011</xref>). We also observed a lateral–medial gradient of atrophy, corresponding to distance from the subventricular zone. Thus, our shape analysis identified three patterns of shape deflation, which may arise from general patterns of neurodegeneration affecting the neostriatum.</p>
<p>In FTLD, we also found specific regional atrophy of potential functional significance, affecting the interconnections of the neostriatum to dorsolateral prefrontal, anterior cingulate and orbitofrontal cortex; motor cortex corresponding to the frontal eye fields in the caudate; and primary motor cortex in the putamen (<xref ref-type="bibr" rid="bibr39-0004867411432076">Looi et al., 2010</xref>). Thus, based upon the findings of general and specific patterns of neostriatal morphological change in FTLD, we suggest correlative neuropathological studies should be conducted to determine the microscopic/molecular bases of these patterns.</p>
<p>Our most recent shape analysis of the clinically diagnosed subtypes of FTLD demonstrated that the majority of the neostriatal atrophy and thus, morphological change, could be attributed to changes in the FTD subtype, and to a lesser extent the PNFA subgroup, in comparison to controls (<xref ref-type="bibr" rid="bibr38-0004867411432076">Looi et al., 2011a</xref>). Again, the shape deflation was most pronounced in the FTD subtype of FTLD, the subtype with the greatest putative frontostriatal dysfunction. The FTD subtype regional atrophy was of functional significance, affecting the regions believed to be interconnected to the frontostriatal circuits. Notably, there was no significant neostriatal shape difference of the SD subtype in comparison with controls, such that neostriatal shape change appeared in the gradient FTD &gt; PNFA &gt;SD ≥ controls. We note, however, the shape analysis was not sufficiently powered to investigate neostriatal shape differences between subtypes of FTLD.</p>
<p>Given that the frontostriatal white matter connects the neostriatum with the neocortex, it is possible that the specific regional atrophy in the neostriatum may also be associated with atrophy in frontostriatal white matter and the frontal cortex (<xref ref-type="bibr" rid="bibr2-0004867411432076">Avants et al., 2010</xref>; <xref ref-type="bibr" rid="bibr47-0004867411432076">Matsuo et al., 2008</xref>; <xref ref-type="bibr" rid="bibr71-0004867411432076">Whitwell et al., 2010</xref>; <xref ref-type="bibr" rid="bibr77-0004867411432076">Zhang et al., 2009</xref>). Similarly, such a relationship may also exist for corticostriatal circuits. The mechanism for these disconnection phenomena may include diaschisis and trans-synaptic degeneration, the process by which anterograde and retrograde neuronal effects arise from neuronal damage (<xref ref-type="bibr" rid="bibr6-0004867411432076">Buren, 1963</xref>). The morphology of the white matter may be assessed by diffusion tensor MRI, whilst cortex morphology may also be quantified. Potentially, then, in addition to the morphology of the neostriatum as a strategic biomarker, the morphology of frontostriatal white matter and the frontal cortex may also serve as biomarkers, linked to clinical features and stage of FTLD.</p>
</sec>
<sec id="section12-0004867411432076" sec-type="conclusions">
<title>Conclusions and future directions</title>
<p>We propose the investigation of the FTD subtype of FTLD as a frontostriatal disorder, through morphological measurement of significant structural components such as the neostriatum, frontostriatal white matter tracts, the frontal cortex and the functions served by these circuits. The neostriatum and connections may prove to be valuable early biomarkers in FTD: for early diagnosis; staging illness; subtyping or endophenotyping based upon the pattern of atrophy; and ultimately, the design of targeted treatments. In relation to subtypes of FTLD without significant neostriatal atrophy, such as SD and to a lesser extent, PNFA, it will be important to explore other circuit dysfunction, such as that of language circuits, as a potential endophenotype. Accordingly, frontostriatal features are not hypothesised as being universal to all subtypes of FTLD. However, frontostriatal disorder may account for at least some features of FTD and PNFA, if not SD. Thus, our proposal converges at the super-ordinate level with the investigation of the selective vulnerability of large-scale human brain networks (<xref ref-type="bibr" rid="bibr61-0004867411432076">Seeley et al., 2009</xref>), and will contribute to understanding of frontostriatal networks as a subset of larger networks. Practically, we have demonstrated methods for quantifying the morphology of the strategically central neostriatum, which can thus serve as a window into the structural, and hence functional integrity, of frontostriatal circuits (<xref ref-type="bibr" rid="bibr39-0004867411432076">Looi et al., 2010</xref>, <xref ref-type="bibr" rid="bibr38-0004867411432076">2011a</xref>). In future, it may also be possible to correlate the structural morphology of frontostriatal circuits with neuropsychological functions and measurements of neuropsychiatric features (depression, apathy, mania) carried by those circuits.</p>
<p>An understanding of the pathophysiology of FTD based on the neostriatum may yield proximate and future insights into treatment strategies. At the proximate level, the quantification of the degree of frontostriatal circuit dysfunction via correlation of the neuroimaging and clinical biomarkers may inform the design of psychological and occupational therapy interventions. In the future, based upon correlation with genotype, molecular pathology and CSF biomarkers, drug treatment targets for abnormal pathophysiology may be identified, the success of treatment of which may be measured by quantification of neostriatal morphology using such methods as we have shown. Highly speculative, but possible based on stem cell treatment in Parkinson disease and other neurodegenerative disease (<xref ref-type="bibr" rid="bibr40-0004867411432076">Lunn et al., 2011</xref>), is the potential targeted promotion of neurogenesis in the subventricular zone (<xref ref-type="bibr" rid="bibr12-0004867411432076">Curtis et al., 2007</xref>) adjacent to the striatum, and the core of the nucleus accumbens (<xref ref-type="bibr" rid="bibr22-0004867411432076">Heimer and Van Hoesen, 2006</xref>) within the striatum; informed by understanding of the patterns of neurodegeneration via the methods we espouse.</p>
<p>In re-conceptualising FTD as a frontostriatal disorder, we believe that in vivo morphology via MRI may serve as a useful interconnection between molecular neuropathology and clinical features; that is, as a useful endophenotype, an approach similar to that adopted in advancing understanding of neuropsychiatric disease (such as in choreoacanthocytosis, bipolar disorder and schizophrenia). In addition, such study will also contribute to the understanding of large-scale human brain networks, of which the frontostriatal circuits serve as a sub-system. <italic>By understanding neural morphology, manifest in the warp and weave of the fabric of the frontostriatal circuits, we may discern the patterns of disease in the tragic tapestry of FTLD</italic>.</p>
</sec>
</body>
<back>
<sec id="section13-0004867411432076">
<title>Author contributions</title>
<p>JCLL conceived, designed and is the guarantor of the FTLD volumetric and shape analysis studies on which the paper has been based and wrote the first draft of this paper. MW (principal shape analyst) and DV (collaborator on shape analysis) were principal investigators on the shape analysis of FTLD on which the paper has been based. LS (software for image pre-processing and analysis) and L-OW (Karolinska University Hospital Huddinge FTLD cohort) were principal investigators of the FTLD studies on which the paper has been based. MDM assisted with writing the paper and produced <xref ref-type="fig" rid="fig6-0004867411432076">Figure 6</xref>. All authors contributed to writing and editing of the paper.</p>
</sec>
<sec id="section14-0004867411432076">
<title>Acknowledgements</title>
<p>Research reported here made use of the SMILE medical imaging laboratory at Karolinska University Hospital, Stockholm, Sweden. JCLL was supported by the Canberra Hospital Specialists Private Practice Trust Fund, ACT health funding, and self-funding for travel and accommodation for research conducted at SMILE and Melbourne Neuropsychiatry Centre. The contributions of the volunteers and collaborators of the morphological studies of FTLD conducted at SMILE are also gratefully acknowledged. Collaborators who contributed to the papers on which this review is, in part, based include: Christian Andersen, Lisa Botes, Phyllis Chua, Eva-Lena Engman, Rajeev Kumar, Olof Lindberg, Eva Örndahl, Per Östberg, Martin Styner, Marc Niethammer, and Bram B. Zandbelt.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="bibr1-0004867411432076">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Alexander</surname><given-names>GE</given-names></name>
<name><surname>Delong</surname><given-names>MR</given-names></name>
<name><surname>Strick</surname><given-names>PL</given-names></name>
</person-group> (<year>1986</year>) <article-title>Parallel organisation of functionally segregated circuits linking basal ganglia and cortex</article-title>. <source>Annual Review of Neuroscience</source> <volume>9</volume>: <fpage>357</fpage>–<lpage>381</lpage>.</citation>
</ref>
<ref id="bibr2-0004867411432076">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Avants</surname><given-names>BB</given-names></name>
<name><surname>Cook</surname><given-names>PA</given-names></name>
<name><surname>Ungar</surname><given-names>L</given-names></name>
<etal/>
</person-group>. (<year>2010</year>) <article-title>Dementia induces correlated reductions in white matter integrity and cortical thickness: A multivariate neuroimaging study with sparse canonical correlation analysis</article-title>. <source>Neuroimage</source> <volume>50</volume>: <fpage>1004</fpage>–<lpage>1016</lpage>.</citation>
</ref>
<ref id="bibr3-0004867411432076">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Aylward</surname><given-names>EH</given-names></name>
</person-group> (<year>2007</year>) <article-title>Change in MRI striatal volumes as a biomarker in preclinical Huntington’s disease</article-title>. <source>Brain Research Bulletin</source> <volume>72</volume>: <fpage>152</fpage>–<lpage>158</lpage>.</citation>
</ref>
<ref id="bibr4-0004867411432076">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Banks</surname><given-names>SJ</given-names></name>
<name><surname>Weintraub</surname><given-names>S</given-names></name>
</person-group> (<year>2008</year>) <article-title>Neuropsychiatric symptoms in behavioral variant frontotemporal dementia and primary progressive aphasia</article-title>. <source>Journal of Geriatric Psychiatry and Neurology</source> <volume>221</volume>: <fpage>133</fpage>–<lpage>141</lpage>.</citation>
</ref>
<ref id="bibr5-0004867411432076">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bozoki</surname><given-names>AC</given-names></name>
<name><surname>Farooq</surname><given-names>MU</given-names></name>
</person-group> (<year>2009</year>) <article-title>Frontotemporal lobar degeneration insights from neuropsychology and neuroimaging</article-title>. <source>International Review of Neurobiology</source> <volume>84</volume>: <fpage>185</fpage>–<lpage>213</lpage>.</citation>
</ref>
<ref id="bibr6-0004867411432076">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Buren</surname><given-names>JMV</given-names></name>
</person-group> (<year>1963</year>) <article-title>Trans-synaptic retrograde degeneration in the visual system of primates</article-title>. <source>Journal of Neurology, Neurosurgery and Psychiatry</source> <volume>26</volume>: <fpage>402</fpage>–<lpage>409</lpage>.</citation>
</ref>
<ref id="bibr7-0004867411432076">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Burrell</surname><given-names>JR</given-names></name>
<name><surname>Hodges</surname><given-names>JR</given-names></name>
</person-group> (<year>2010</year>) <article-title>From FUS to Fibs: what’s new in frontotemporal dementia</article-title>. <source>Journal of Alzheimer’s Disease</source> <volume>21</volume>: <fpage>349</fpage>–<lpage>360</lpage>.</citation>
</ref>
<ref id="bibr8-0004867411432076">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cairns</surname><given-names>NJ</given-names></name>
<name><surname>Bigio</surname><given-names>EH</given-names></name>
<name><surname>Mackenzie</surname><given-names>IRA</given-names></name>
<etal/>
</person-group>. (<year>2007</year>) <article-title>Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration</article-title>. <source>Acta Neuropathologica</source> <volume>114</volume>: <fpage>5</fpage>–<lpage>22</lpage>.</citation>
</ref>
<ref id="bibr9-0004867411432076">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Choi</surname><given-names>J</given-names></name>
<name><surname>Kim</surname><given-names>S</given-names></name>
<name><surname>Yoo</surname><given-names>S</given-names></name>
<etal/>
</person-group>. (<year>2007</year>) <article-title>Shape deformity of the corpus striatum in obsessive–compulsive disorder</article-title>. <source>Psychiatry Research: Neuroimaging</source> <volume>155</volume>: <fpage>257</fpage>–<lpage>264</lpage>.</citation>
</ref>
<ref id="bibr10-0004867411432076">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chow</surname><given-names>TW</given-names></name>
<name><surname>Izenberg</surname><given-names>A</given-names></name>
<name><surname>Binns</surname><given-names>MA</given-names></name>
<etal/>
</person-group>. (<year>2008</year>) <article-title>Magnetic resonance imaging in frontotemporal dementia shows subcortical atrophy</article-title>. <source>Dementia and Geriatric Cognitive Disorders</source> <volume>26</volume>: <fpage>79</fpage>–<lpage>88</lpage>.</citation>
</ref>
<ref id="bibr11-0004867411432076">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cummings</surname><given-names>JL</given-names></name>
</person-group> (<year>1993</year>) <article-title>Frontal subcortical circuits and human behaviour</article-title>. <source>Archives of Neurology</source> <volume>5</volume>: <fpage>873</fpage>–<lpage>880</lpage>.</citation>
</ref>
<ref id="bibr12-0004867411432076">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Curtis</surname><given-names>MA</given-names></name>
<name><surname>Faull</surname><given-names>RLM</given-names></name>
<name><surname>Eriksson</surname><given-names>PS</given-names></name>
</person-group> (<year>2007</year>) <article-title>The effect of neurodegenerative diseases on the subventricular zone</article-title>. <source>Nature Reviews Neuroscience</source> <volume>8</volume>: <fpage>712</fpage>–<lpage>723</lpage>.</citation>
</ref>
<ref id="bibr13-0004867411432076">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Davion</surname><given-names>S</given-names></name>
<name><surname>Johnson</surname><given-names>N</given-names></name>
<name><surname>Weintraub</surname><given-names>S</given-names></name>
<etal/>
</person-group>. (<year>2007</year>) <article-title>Clinicopathologic correlation in PGRN mutations</article-title>. <source>Neurology</source> <volume>69</volume>: <fpage>1113</fpage>–<lpage>1121</lpage>.</citation>
</ref>
<ref id="bibr14-0004867411432076">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Douaud</surname><given-names>G</given-names></name>
<name><surname>Gaura</surname><given-names>V</given-names></name>
<name><surname>Ribeiro</surname><given-names>MJ</given-names></name>
<etal/>
</person-group>. (<year>2006</year>) <article-title>Distribution of grey matter atrophy in Huntington’s disease patients: A combined ROI-based and voxel-based morphometric study</article-title>. <source>Neuroimage</source> <volume>32</volume>: <fpage>1562</fpage>–<lpage>1575</lpage>.</citation>
</ref>
<ref id="bibr15-0004867411432076">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Draganski</surname><given-names>B</given-names></name>
<name><surname>Kherif</surname><given-names>F</given-names></name>
<name><surname>Kloppel</surname><given-names>S</given-names></name>
<etal/>
</person-group>. (<year>2008</year>) <article-title>Evidence for segregated and integrative connectivity patterns in the human basal ganglia</article-title>. <source>Journal of Neuroscience</source> <volume>28</volume>: <fpage>7143</fpage>–<lpage>7152</lpage>.</citation>
</ref>
<ref id="bibr16-0004867411432076">
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Feynman</surname><given-names>RP</given-names></name>
</person-group> (<year>1994</year>) <source>The Character of Physical Law</source>. <publisher-loc>New York</publisher-loc>: <publisher-name>Modern Library</publisher-name>.</citation>
</ref>
<ref id="bibr17-0004867411432076">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Garibotto</surname><given-names>V</given-names></name>
<name><surname>Borroni</surname><given-names>B</given-names></name>
<name><surname>Agosti</surname><given-names>C</given-names></name>
<etal/>
</person-group>. (<year>2011</year>) <article-title>Subcortical and deep cortical atrophy in frontotemporal lobar degeneration</article-title>. <source>Neurobiology of Aging</source> <volume>32</volume>: <fpage>875</fpage>–<lpage>884</lpage>.</citation>
</ref>
<ref id="bibr18-0004867411432076">
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Ghetti</surname><given-names>B</given-names></name>
<name><surname>Hutton</surname><given-names>ML</given-names></name>
<name><surname>Wszolek</surname><given-names>ZK</given-names></name>
</person-group> (<year>2003</year>) <article-title>Frontotemporal dementia and Parkinsonism linked to chromosome 17 associated with the tau gene mutations (FTDP-17T)</article-title>. In: <person-group person-group-type="editor">
<name><surname>Dickson</surname><given-names>DW</given-names></name>
</person-group> (ed.) <source>Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders</source>. <publisher-loc>Basel</publisher-loc>: <publisher-name>ISN Neuropath Press</publisher-name>, pp.<fpage>86</fpage>–<lpage>102</lpage>.</citation>
</ref>
<ref id="bibr19-0004867411432076">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gorno-Tempini</surname><given-names>ML</given-names></name>
<name><surname>Brambati</surname><given-names>SM</given-names></name>
<name><surname>Ginex</surname><given-names>V</given-names></name>
<etal/>
</person-group>. (<year>2008</year>) <article-title>The logopenic/phonological variant of primary progressive aphasia</article-title>. <source>Neurology</source> <volume>71</volume>: <fpage>1227</fpage>–<lpage>1234</lpage>.</citation>
</ref>
<ref id="bibr20-0004867411432076">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Haber</surname><given-names>S</given-names></name>
</person-group> (<year>2003</year>) <article-title>The primate basal ganglia: parallel and integrative networks</article-title>. <source>Journal of Chemical Neuroanatomy</source> <volume>26</volume>: <fpage>317</fpage>–<lpage>330</lpage>.</citation>
</ref>
<ref id="bibr21-0004867411432076">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Haber</surname><given-names>SN</given-names></name>
<name><surname>Fudge</surname><given-names>JL</given-names></name>
<name><surname>McFarland</surname><given-names>NR</given-names></name>
</person-group> (<year>2000</year>) <article-title>Striatonigrostriatal pathways in primates form an ascending spiral from the shell to the dorsolateral striatum</article-title>. <source>Journal of Neuroscience</source> <volume>20</volume>: <fpage>2369</fpage>–<lpage>2382</lpage>.</citation>
</ref>
<ref id="bibr22-0004867411432076">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Heimer</surname><given-names>L</given-names></name>
<name><surname>Van Hoesen</surname><given-names>GW</given-names></name>
</person-group> (<year>2006</year>) <article-title>The limbic lobe and its output channels: implications for emotional function and adaptive behaviour</article-title>. <source>Neuroscience and Biobehavioral Reviews</source> <volume>30</volume>: <fpage>126</fpage>–<lpage>147</lpage>.</citation>
</ref>
<ref id="bibr23-0004867411432076">
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Hodges</surname><given-names>JR</given-names></name>
<name><surname>Patterson</surname><given-names>K</given-names></name>
</person-group> (<year>2007</year>) <article-title>The neuropsychology of frontotemporal dementia</article-title>. In: <person-group person-group-type="editor">
<name><surname>Hodges</surname><given-names>JR</given-names></name>
</person-group> (ed.) <source>Frontotemporal Dementia Syndromes</source>. <publisher-loc>Cambridge</publisher-loc>: <publisher-name>Cambridge University Press</publisher-name>, pp.<fpage>102</fpage>–<lpage>133</lpage>.</citation>
</ref>
<ref id="bibr24-0004867411432076">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hu</surname><given-names>WT</given-names></name>
<name><surname>Chen-Plotkin</surname><given-names>A</given-names></name>
<name><surname>Arnold</surname><given-names>SE</given-names></name>
<etal/>
</person-group>. (<year>2010</year>) <article-title>Biomarker discovery for Alzheimer’s disease, frontotemporal lobar degeneration, and Parkinson’s disease</article-title>. <source>Acta Neuropathologica</source> <volume>120</volume>: <fpage>385</fpage>–<lpage>399</lpage>.</citation>
</ref>
<ref id="bibr25-0004867411432076">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hu</surname><given-names>WT</given-names></name>
<name><surname>Trojanowski</surname><given-names>JQ</given-names></name>
<name><surname>Shaw</surname><given-names>LM</given-names></name>
</person-group> (<year>2011</year>) <article-title>Biomarkers in frontotemporal lobar degenerations – progress and challenges</article-title>. <source>Progress in Neurobiology</source>. <comment>Epub ahead of print</comment>. DOI 10.1016/j.pneurobio.2011.04.012<pub-id pub-id-type="doi">10.1016/j.pneurobio.2011.04.012</pub-id></citation>
</ref>
<ref id="bibr26-0004867411432076">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hwang</surname><given-names>J</given-names></name>
<name><surname>Lyoo</surname><given-names>IK</given-names></name>
<name><surname>Dager</surname><given-names>SR</given-names></name>
<etal/>
</person-group>. (<year>2006</year>) <article-title>Basal ganglia shape alterations in bipolar disorder</article-title>. <source>American Journal of Psychiatry</source> <volume>163</volume>: <fpage>276</fpage>–<lpage>285</lpage>.</citation>
</ref>
<ref id="bibr27-0004867411432076">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Johns</surname><given-names>EK</given-names></name>
<name><surname>Phillips</surname><given-names>NA</given-names></name>
<name><surname>Belleville</surname><given-names>S</given-names></name>
<etal/>
</person-group>. (<year>2009</year>) <article-title>Executive functions in frontotemporal dementia and Lewy body dementia</article-title>. <source>Neuropsychology</source> <volume>23</volume>: <fpage>765</fpage>–<lpage>777</lpage>.</citation>
</ref>
<ref id="bibr28-0004867411432076">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Josephs</surname><given-names>KA</given-names></name>
<name><surname>Lin</surname><given-names>W-L</given-names></name>
<name><surname>Ahmed</surname><given-names>Z</given-names></name>
<etal/>
</person-group>. (<year>2008</year>) <article-title>Frontotemporal lobar degeneration with ubiquitin-positive, but TDP-43-negative inclusions</article-title>. <source>Acta Neuropathologica</source> <volume>116</volume>: <fpage>159</fpage>–<lpage>167</lpage>.</citation>
</ref>
<ref id="bibr29-0004867411432076">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Josephs</surname><given-names>KA</given-names></name>
<name><surname>Whitwell</surname><given-names>JL</given-names></name>
<name><surname>Parisi</surname><given-names>JE</given-names></name>
<etal/>
</person-group>. (<year>2010</year>) <article-title>Caudate atrophy on MRI is a characteristic feature of FTLD-FUS</article-title>. <source>European Journal of Neurology</source> <volume>17</volume>: <fpage>969</fpage>–<lpage>975</lpage>.</citation>
</ref>
<ref id="bibr30-0004867411432076">
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Koziol</surname><given-names>LF</given-names></name>
<name><surname>Budding</surname><given-names>DE</given-names></name>
</person-group> (<year>2009</year>) <source>Subcortical Structures and Cognition</source>. <publisher-loc>New York</publisher-loc>: <publisher-name>Springer</publisher-name>.</citation>
</ref>
<ref id="bibr31-0004867411432076">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Leverenz</surname><given-names>JB</given-names></name>
<name><surname>Yu</surname><given-names>CE</given-names></name>
<name><surname>Montine</surname><given-names>TJ</given-names></name>
<etal/>
</person-group>. (<year>2007</year>) <article-title>A novel progranulin mutation associated with variable clinical presentation and tau, TDP43 and alpha-synuclein pathology</article-title>. <source>Brain</source> <volume>130</volume>: <fpage>1360</fpage>–<lpage>1374</lpage>.</citation>
</ref>
<ref id="bibr32-0004867411432076">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Levitt</surname><given-names>JJ</given-names></name>
<name><surname>Styner</surname><given-names>M</given-names></name>
<name><surname>Niethammer</surname><given-names>M</given-names></name>
<etal/>
</person-group>. (<year>2009</year>) <article-title>Shape abnormalities of caudate nucleus in schizotypal personality disorder</article-title>. <source>Schizophrenia Research</source> <volume>110</volume>: <fpage>127</fpage>–<lpage>139</lpage>.</citation>
</ref>
<ref id="bibr33-0004867411432076">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Libon</surname><given-names>DJ</given-names></name>
<name><surname>Xie</surname><given-names>SX</given-names></name>
<name><surname>Wang</surname><given-names>X</given-names></name>
<etal/>
</person-group>. (<year>2009</year>) <article-title>Neuropsychological decline in frontotemporal lobar degeneration: A longitudinal analysis</article-title>. <source>Neuropsychology</source> <volume>23</volume>: <fpage>337</fpage>–<lpage>346</lpage>.</citation>
</ref>
<ref id="bibr34-0004867411432076">
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Looi</surname><given-names>JCL</given-names></name>
</person-group> (<year>2011</year>) <source>Quantitative Neostriatal Neuroanatomy as a Basis of Frontostriatal Circuit Dysfunction in Neuropsychiatric Disease</source>. <publisher-loc>Academic Unit of Psychological Medicine, ANU Medical School, Canberra</publisher-loc>: <publisher-name>Australian National University</publisher-name>, p.<fpage>262</fpage>.</citation>
</ref>
<ref id="bibr35-0004867411432076">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Looi</surname><given-names>JCL</given-names></name>
<name><surname>Lindberg</surname><given-names>O</given-names></name>
<name><surname>Zandbelt</surname><given-names>BB</given-names></name>
<etal/>
</person-group>. (<year>2008</year>) <article-title>Caudate nucleus volumes in frontotemporal lobar degeneration: differential atrophy in subtypes</article-title>. <source>American Journal of Neuroradiology</source> <volume>29</volume>: <fpage>1537</fpage>–<lpage>1543</lpage>.</citation>
</ref>
<ref id="bibr36-0004867411432076">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Looi</surname><given-names>JCL</given-names></name>
<name><surname>Macfarlane</surname><given-names>MD</given-names></name>
<name><surname>Walterfang</surname><given-names>M</given-names></name>
<etal/>
</person-group>. (<year>2011b</year>) <article-title>Morphometric analysis of subcortical structures in progressive supranuclear palsy: in vivo evidence of neostriatal and mesencephalic atrophy</article-title>. <source>Psychiatry Research: Neuroimaging</source> <volume>194</volume>: <fpage>163</fpage>–<lpage>175</lpage>.</citation>
</ref>
<ref id="bibr37-0004867411432076">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Looi</surname><given-names>JCL</given-names></name>
<name><surname>Svensson</surname><given-names>L</given-names></name>
<name><surname>Lindberg</surname><given-names>O</given-names></name>
<etal/>
</person-group>. (<year>2009</year>) <article-title>Putaminal volume in frontotemporal lobar degeneration and Alzheimer disease: Differential volumes in dementia subtypes and controls</article-title>. <source>American Journal of Neuroradiology</source> <volume>30</volume>: <fpage>1552</fpage>–<lpage>1560</lpage>.</citation>
</ref>
<ref id="bibr38-0004867411432076">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Looi</surname><given-names>JCL</given-names></name>
<name><surname>Walterfang</surname><given-names>M</given-names></name>
<name><surname>Styner</surname><given-names>M</given-names></name>
<etal/>
</person-group>. (<year>2011a</year>) <article-title>Shape analysis of the neostriatum in subtypes of frontotemporal lobar degeneration: Neuroanatomically significant regional morphologic change</article-title>. <source>Psychiatry Research: Neuroimaging</source> <volume>191</volume>: <fpage>98</fpage>–<lpage>111</lpage>.</citation>
</ref>
<ref id="bibr39-0004867411432076">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Looi</surname><given-names>JCL</given-names></name>
<name><surname>Walterfang</surname><given-names>M</given-names></name>
<name><surname>Styner</surname><given-names>M</given-names></name>
<etal/>
</person-group>. (<year>2010</year>) <article-title>Shape analysis of the neostriatum in frontotemporal lobar degeneration, Alzheimer’s disease, and controls</article-title>. <source>Neuroimage</source> <volume>51</volume>: <fpage>970</fpage>–<lpage>986</lpage>.</citation>
</ref>
<ref id="bibr40-0004867411432076">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lunn</surname><given-names>JS</given-names></name>
<name><surname>Sakowski</surname><given-names>SA</given-names></name>
<name><surname>Hur</surname><given-names>J</given-names></name>
<etal/>
</person-group>. (<year>2011</year>) <article-title>Stem cell technology for neurodegenerative diseases</article-title>. <source>Annals of Neurology</source> <volume>70</volume>: <fpage>353</fpage>–<lpage>361</lpage>.</citation>
</ref>
<ref id="bibr41-0004867411432076">
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Macedo</surname><given-names>MN</given-names></name>
<name><surname>Kim</surname><given-names>EJ</given-names></name>
<name><surname>Seeley</surname><given-names>WW</given-names></name>
</person-group> (<year>2009</year>) <article-title>Neuropathology of dementia</article-title>. In: <person-group person-group-type="editor">
<name><surname>Miller</surname><given-names>BL</given-names></name>
<name><surname>Boeve</surname><given-names>BF</given-names></name>
</person-group> (eds) <source>The Behavioral Neurology of Dementia</source>. <publisher-loc>Cambridge</publisher-loc>: <publisher-name>Cambridge University Press</publisher-name>, pp.<fpage>142</fpage>–<lpage>160</lpage>.</citation>
</ref>
<ref id="bibr42-0004867411432076">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mackenzie</surname><given-names>IRA</given-names></name>
<name><surname>Baker</surname><given-names>M</given-names></name>
<name><surname>Pickering-Brown</surname><given-names>S</given-names></name>
<etal/>
</person-group>. (<year>2006</year>) <article-title>The neuropathology of frontotemporal lobar degeneration caused by mutations in the progranulin gene</article-title>. <source>Brain</source> <volume>129</volume>: <fpage>3081</fpage>–<lpage>3090</lpage>.</citation>
</ref>
<ref id="bibr43-0004867411432076">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mackenzie</surname><given-names>IRA</given-names></name>
<name><surname>Rademakers</surname><given-names>R</given-names></name>
</person-group> (<year>2007</year>) <article-title>The molecular genetics and neuropathology of frontotemporal lobar degeneration: recent developments</article-title>. <source>Neurogenetics</source> <volume>8</volume>: <fpage>237</fpage>–<lpage>248</lpage>.</citation>
</ref>
<ref id="bibr44-0004867411432076">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mamah</surname><given-names>D</given-names></name>
<name><surname>Harms</surname><given-names>M</given-names></name>
<name><surname>Wang</surname><given-names>L</given-names></name>
<etal/>
</person-group>. (<year>2008</year>) <article-title>Basal ganglia shape abnormalities in the unaffected siblings of schizophrenia patients</article-title>. <source>Biological Psychiatry</source> <volume>64</volume>: <fpage>111</fpage>–<lpage>120</lpage>.</citation>
</ref>
<ref id="bibr45-0004867411432076">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Marczinski</surname><given-names>CA</given-names></name>
<name><surname>Davidson</surname><given-names>W</given-names></name>
<name><surname>Kertesz</surname><given-names>A</given-names></name>
</person-group> (<year>2004</year>) <article-title>A longitudinal study of behavior in frontotemporal dementia and primary progressive aphasia</article-title>. <source>Cognitive and Behavioral Neurology</source> <volume>17</volume>: <fpage>185</fpage>–<lpage>190</lpage>.</citation>
</ref>
<ref id="bibr46-0004867411432076">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Marra</surname><given-names>C</given-names></name>
<name><surname>Quaranta</surname><given-names>D</given-names></name>
<name><surname>Zinno</surname><given-names>M</given-names></name>
<etal/>
</person-group>. (<year>2007</year>) <article-title>Clusters of cognitive and behavioral disorders clearly distinguish primary progressive aphasia from frontal lobe dementia, and Alzheimer’s disease</article-title>. <source>Dementia and Geriatric Cognitive Disorders</source> <volume>24</volume>: <fpage>317</fpage>–<lpage>326</lpage>.</citation>
</ref>
<ref id="bibr47-0004867411432076">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Matsuo</surname><given-names>K</given-names></name>
<name><surname>Mizuno</surname><given-names>T</given-names></name>
<name><surname>Yamada</surname><given-names>K</given-names></name>
<etal/>
</person-group>. (<year>2008</year>) <article-title>Cerebral white matter damage in frontotemporal dementia assessed by diffusion tensor tractography</article-title>. <source>Neuroradiology</source> <volume>50</volume>: <fpage>605</fpage>–<lpage>611</lpage>.</citation>
</ref>
<ref id="bibr48-0004867411432076">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mesulam</surname><given-names>M</given-names></name>
</person-group> (<year>2009</year>) <article-title>Defining neurocognitive networks in the BOLD new world of computed connectivity</article-title>. <source>Neuron</source> <volume>62</volume>: <fpage>1</fpage>–<lpage>3</lpage>.</citation>
</ref>
<ref id="bibr49-0004867411432076">
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Mocellin</surname><given-names>R</given-names></name>
<name><surname>Scholes</surname><given-names>A</given-names></name>
<name><surname>Velakoulis</surname><given-names>D</given-names></name>
</person-group> (<year>2008</year>) <source>Quality Dementia Care: Understanding Younger Onset Dementia</source>. <publisher-loc>Melbourne</publisher-loc>: <publisher-name>Alzheimer’s Association Australia</publisher-name>.</citation>
</ref>
<ref id="bibr50-0004867411432076">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Neary</surname><given-names>D</given-names></name>
<name><surname>Snowden</surname><given-names>JS</given-names></name>
<name><surname>Gustafson</surname><given-names>L</given-names></name>
<etal/>
</person-group>. (<year>1998</year>) <article-title>Frontotemporal lobar degeneration – a consensus on clinical diagnostic criteria</article-title>. <source>Neurology</source> <volume>51</volume>: <fpage>1546</fpage>–<lpage>1554</lpage>.</citation>
</ref>
<ref id="bibr51-0004867411432076">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Neumann</surname><given-names>M</given-names></name>
<name><surname>Tolnay</surname><given-names>M</given-names></name>
<name><surname>Mackenzie</surname><given-names>IRA</given-names></name>
</person-group> (<year>2009</year>) <article-title>The molecular basis of frontotemporal dementia</article-title>. <source>Expert Reviews in Molecular Medicine</source> <volume>11</volume>: <fpage>1</fpage>–<lpage>22</lpage>.</citation>
</ref>
<ref id="bibr52-0004867411432076">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rabinovici</surname><given-names>GD</given-names></name>
<name><surname>Miller</surname><given-names>BL</given-names></name>
</person-group> (<year>2010</year>) <article-title>Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis and management</article-title>. <source>CNS Drugs</source> <volume>24</volume>: <fpage>375</fpage>–<lpage>398</lpage>.</citation>
</ref>
<ref id="bibr53-0004867411432076">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rabinovici</surname><given-names>GD</given-names></name>
<name><surname>Seeley</surname><given-names>WW</given-names></name>
<name><surname>Kim</surname><given-names>EJ</given-names></name>
<etal/>
</person-group>. (<year>2007</year>) <article-title>Distinct MRI atrophy patterns in autopsy-proven Alzheimer’s disease and frontotemporal lobar degeneration</article-title>. <source>American Journal of Alzheimer’s Disease and other Dementias</source> <volume>22</volume>: <fpage>474</fpage>–<lpage>478</lpage>.</citation>
</ref>
<ref id="bibr54-0004867411432076">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rankin</surname><given-names>KP</given-names></name>
<name><surname>Gorno-Tempini</surname><given-names>ML</given-names></name>
<name><surname>Allison</surname><given-names>SC</given-names></name>
<etal/>
</person-group>. (<year>2006</year>) <article-title>Structural anatomy of empathy in neurodegenerative disease</article-title>. <source>Brain</source> <volume>129</volume>: <fpage>2945</fpage>–<lpage>2956</lpage>.</citation>
</ref>
<ref id="bibr55-0004867411432076">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rankin</surname><given-names>KP</given-names></name>
<name><surname>Santos-Modesitt</surname><given-names>W</given-names></name>
<name><surname>Kramer</surname><given-names>JH</given-names></name>
<etal/>
</person-group>. (<year>2008</year>) <article-title>Spontaneous social behaviors discriminate “behavioral dementias” from psychiatric disorders and other dementias</article-title>. <source>Journal of Clinical Psychiatry</source> <volume>69</volume>: <fpage>60</fpage>–<lpage>73</lpage>.</citation>
</ref>
<ref id="bibr56-0004867411432076">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rosen</surname><given-names>HJ</given-names></name>
<name><surname>Allison</surname><given-names>SC</given-names></name>
<name><surname>Ogar</surname><given-names>JM</given-names></name>
<etal/>
</person-group>. (<year>2006</year>) <article-title>Behavioral features in semantic dementia vs other forms of progressive aphasias</article-title>. <source>Neurology</source> <volume>67</volume>: <fpage>198</fpage>–<lpage>208</lpage>.</citation>
</ref>
<ref id="bibr57-0004867411432076">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schroeter</surname><given-names>ML</given-names></name>
<name><surname>Raczka</surname><given-names>K</given-names></name>
<name><surname>Neumann</surname><given-names>J</given-names></name>
<etal/>
</person-group>. (<year>2007</year>) <article-title>Towards a nosology for frontotemporal lobar degenerations – A meta-analysis involving 267 subjects</article-title>. <source>Neuroimage</source> <volume>36</volume>: <fpage>497</fpage>–<lpage>510</lpage>.</citation>
</ref>
<ref id="bibr58-0004867411432076">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Seelaar</surname><given-names>H</given-names></name>
<name><surname>Jurgen Schelhaas</surname><given-names>H</given-names></name>
<name><surname>Azmani</surname><given-names>A</given-names></name>
<etal/>
</person-group>. (<year>2007</year>) <article-title>TDP-43 pathology in familial frontotemporal dementia and motor neuron disease without progranulin mutations</article-title>. <source>Brain</source> <volume>130</volume>: <fpage>1375</fpage>–<lpage>1385</lpage>.</citation>
</ref>
<ref id="bibr59-0004867411432076">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Seeley</surname><given-names>WW</given-names></name>
<name><surname>Carlin</surname><given-names>DA</given-names></name>
<name><surname>Allman</surname><given-names>JM</given-names></name>
<etal/>
</person-group>. (<year>2006</year>) <article-title>Early frontotemporal dementia targets neurons unique to apes and humans</article-title>. <source>Annals of Neurology</source> <volume>60</volume>: <fpage>660</fpage>–<lpage>667</lpage>.</citation>
</ref>
<ref id="bibr60-0004867411432076">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Seeley</surname><given-names>WW</given-names></name>
<name><surname>Crawford</surname><given-names>R</given-names></name>
<name><surname>Rascovsky</surname><given-names>K</given-names></name>
<etal/>
</person-group>. (<year>2008</year>) <article-title>Frontal paralimbic network atrophy in very mild behavioral variant frontotemporal dementia</article-title>. <source>Archives of Neurology</source> <volume>65</volume>: <fpage>249</fpage>–<lpage>255</lpage>.</citation>
</ref>
<ref id="bibr61-0004867411432076">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Seeley</surname><given-names>WW</given-names></name>
<name><surname>Crawford</surname><given-names>RK</given-names></name>
<name><surname>Zhou</surname><given-names>J</given-names></name>
<etal/>
</person-group>. (<year>2009</year>) <article-title>Neurodegenerative diseases target large-scale human brain networks</article-title>. <source>Neuron</source> <volume>62</volume>: <fpage>42</fpage>–<lpage>52</lpage>.</citation>
</ref>
<ref id="bibr62-0004867411432076">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Styner</surname><given-names>M</given-names></name>
<name><surname>Oguz</surname><given-names>I</given-names></name>
<name><surname>Xu</surname><given-names>S</given-names></name>
<etal/>
</person-group>. (<year>2006</year>) <article-title>Framework for the statistical shape analysis of brain structures using SPHARM-PDM</article-title>. <source>Insight Journal</source>: <fpage>1</fpage>–<lpage>21</lpage>.</citation>
</ref>
<ref id="bibr63-0004867411432076">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tekin</surname><given-names>S</given-names></name>
<name><surname>Cummings</surname><given-names>JL</given-names></name>
</person-group> (<year>2002</year>) <article-title>Frontal–subcortical neuronal circuits and clinical neuropsychiatry – An update</article-title>. <source>Journal of Psychosomatic Research</source> <volume>53</volume>: <fpage>647</fpage>–<lpage>654</lpage>.</citation>
</ref>
<ref id="bibr64-0004867411432076">
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Thompson</surname><given-names>DW</given-names></name>
</person-group> (<year>1945</year>) <source>On Growth and Form: A New Edition</source>. <publisher-loc>Cambridge</publisher-loc>: <publisher-name>Cambridge University Press</publisher-name>.</citation>
</ref>
<ref id="bibr65-0004867411432076">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Turing</surname><given-names>AM</given-names></name>
</person-group> (<year>1952</year>) <article-title>The chemical basis of morphogenesis</article-title>. <source>Philosophical Transactions of the Royal Society of London: Series B, Biological Sciences</source> <volume>237</volume>: <fpage>37</fpage>–<lpage>72</lpage>.</citation>
</ref>
<ref id="bibr66-0004867411432076">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Utter</surname><given-names>AA</given-names></name>
<name><surname>Basso</surname><given-names>MA</given-names></name>
</person-group> (<year>2008</year>) <article-title>The basal ganglia: an overview of circuits and function</article-title>. <source>Neuroscience and Biobehavioral Reviews</source> <volume>32</volume>: <fpage>333</fpage>–<lpage>342</lpage>.</citation>
</ref>
<ref id="bibr67-0004867411432076">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Villemagne</surname><given-names>VL</given-names></name>
<name><surname>Ataka</surname><given-names>S</given-names></name>
<name><surname>Mizuno</surname><given-names>T</given-names></name>
<etal/>
</person-group>. (<year>2009</year>) <article-title>High striatal amyloid-peptide deposition across different autosomal Alzheimer disease mutation types</article-title>. <source>Archives of Neurology</source> <volume>66</volume>: <fpage>1537</fpage>–<lpage>1544</lpage>.</citation>
</ref>
<ref id="bibr68-0004867411432076">
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>von Braunmühl</surname><given-names>A</given-names></name>
</person-group> (<year>1930</year>) <article-title>Picksche Krankheit</article-title>. In: <person-group person-group-type="editor">
<name><surname>Bumke</surname><given-names>O</given-names></name>
</person-group> (ed.) <source>Handbuch der Geisteskrankheiten</source>. <publisher-loc>Berlin</publisher-loc>: <publisher-name>Springer</publisher-name>, pp.<fpage>673</fpage>–<lpage>715</lpage>.</citation>
</ref>
<ref id="bibr69-0004867411432076">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Walterfang</surname><given-names>M</given-names></name>
<name><surname>Looi</surname><given-names>JCL</given-names></name>
<name><surname>Styner</surname><given-names>M</given-names></name>
<etal/>
</person-group>. (<year>2011</year>) <article-title>Shape alterations in the striatum in chorea-acanthocytosis</article-title>. <source>Psychiatry Research: Neuroimaging</source> <volume>192</volume>: <fpage>29</fpage>–<lpage>36</lpage>.</citation>
</ref>
<ref id="bibr70-0004867411432076">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Weiser</surname><given-names>M</given-names></name>
<name><surname>van Os</surname><given-names>J</given-names></name>
<name><surname>Davidson</surname><given-names>M</given-names></name>
</person-group> (<year>2005</year>) <article-title>Time for a shift in focus in schizophrenia: from narrow phenotypes to broad endophenotypes</article-title>. <source>British Journal of Psychiatry</source> <volume>187</volume>: <fpage>203</fpage>–<lpage>205</lpage>.</citation>
</ref>
<ref id="bibr71-0004867411432076">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Whitwell</surname><given-names>JL</given-names></name>
<name><surname>Avula</surname><given-names>R</given-names></name>
<name><surname>Senjem</surname><given-names>ML</given-names></name>
<etal/>
</person-group>. (<year>2010</year>) <article-title>Gray and white matter water diffusion in the syndromic variants of frontotemporal dementia</article-title>. <source>Neurology</source> <volume>74</volume>: <fpage>1279</fpage>–<lpage>1287</lpage>.</citation>
</ref>
<ref id="bibr72-0004867411432076">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Whitwell</surname><given-names>JL</given-names></name>
<name><surname>Jack</surname><given-names>CR</given-names><suffix>Jr</suffix></name>
<name><surname>Senjem</surname><given-names>ML</given-names></name>
<etal/>
</person-group>. (<year>2009a</year>) <article-title>MRI correlates of protein deposition and disease severity in postmortem frontotemporal lobar degeneration</article-title>. <source>Neurodegenerative Diseases</source> <volume>6</volume>: <fpage>106</fpage>–<lpage>117</lpage>.</citation>
</ref>
<ref id="bibr73-0004867411432076">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Whitwell</surname><given-names>JL</given-names></name>
<name><surname>Jack</surname><given-names>CR</given-names><suffix>Jr</suffix></name>
<name><surname>Boeve</surname><given-names>BF</given-names></name>
<etal/>
</person-group>. (<year>2009b</year>) <article-title>Voxel-based morphometry patterns of atrophy in FTLD with mutations in MAPT or PGRN</article-title>. <source>Neurology</source> <volume>72</volume>: <fpage>813</fpage>–<lpage>820</lpage>.</citation>
</ref>
<ref id="bibr74-0004867411432076">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Whitwell</surname><given-names>JL</given-names></name>
<name><surname>Przybelski</surname><given-names>SA</given-names></name>
<name><surname>Weigand</surname><given-names>SD</given-names></name>
<etal/>
</person-group>. (<year>2009c</year>) <article-title>Distinct anatomical subtypes of the behavioural variant of frontotemporal dementia: a cluster analysis study</article-title>. <source>Brain</source> <volume>132</volume>: <fpage>2932</fpage>–<lpage>2946</lpage>.</citation>
</ref>
<ref id="bibr75-0004867411432076">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wittenberg</surname><given-names>D</given-names></name>
<name><surname>Possin</surname><given-names>KL</given-names></name>
<name><surname>Rascovsky</surname><given-names>K</given-names></name>
<etal/>
</person-group>. (<year>2008</year>) <article-title>The early neuropsychological and behavioral characteristics of frontotemporal dementia</article-title>. <source>Neuropsychology Review</source> <volume>18</volume>: <fpage>91</fpage>–<lpage>102</lpage>.</citation>
</ref>
<ref id="bibr76-0004867411432076">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yokota</surname><given-names>O</given-names></name>
<name><surname>Tsuchiya</surname><given-names>K</given-names></name>
<name><surname>Arai</surname><given-names>T</given-names></name>
<etal/>
</person-group>. (<year>2009</year>) <article-title>Clinicopathological characterization of Pick’s disease versus frontotemporal lobar degeneration with ubiquitin/TDP-43-positive inclusions</article-title>. <source>Acta Neuropathologica</source> <volume>117</volume>: <fpage>429</fpage>–<lpage>444</lpage>.</citation>
</ref>
<ref id="bibr77-0004867411432076">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>Y</given-names></name>
<name><surname>Schuff</surname><given-names>N</given-names></name>
<name><surname>Du</surname><given-names>AT</given-names></name>
<etal/>
</person-group>. (<year>2009</year>) <article-title>White matter damage in frontotemporal dementia and Alzheimer’s disease measured by diffusion MRI</article-title>. <source>Brain</source> <volume>132</volume>: <fpage>2579</fpage>–<lpage>2592</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>